AUPH Aurinia Pharmaceuticals Inc

6.32
-0.29  -4%
Previous Close 6.61
Open 6.62
Price To Book 4.4
Market Cap 540771842
Shares 85,500,228
Volume 398,320
Short Ratio
Av. Daily Volume 1,075,634

NewsSee all news

  1. Is Aurinia Pharmaceuticals a Buy?
  2. Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Economic Growth
  3. Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial
  4. Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
  5. Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594566
  2. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19534252
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 19533288
  4. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181212101
  5. SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] 181212061

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released January 22, 2019. Primary endpoint not met, secondary met.
Voclosporin Ophthalmic Solution (VOS)
Dry eye syndrome
Phase 2 trial initiation announced June 2018. Interim data readouts are anticipated from mid-2019.
Voclosporin
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURION trial
Lupus
Phase 3 completion of enrollment announced September 25, 2018. Data due 4Q 2019.
Voclosporin - AURORA
Lupus
Phase 2 trial enrollment has commenced - noted June 25, 2018.
Voclosporin - AURORA 2
Lupus

Latest News

  1. Is Aurinia Pharmaceuticals a Buy?
  2. Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Economic Growth
  3. Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial
  4. Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
  5. Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome
  6. Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
  7. My Rx for How to Buy Aurinia Pharmaceuticals on Its Breakout
  8. 4 Pharma Stocks Getting a Boost on Thursday (12/20/18)
  9. Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
  10. Aurinia Establishes at-the-Market Facility
  11. Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  12. Aurinia to Participate in November Investor Conferences
  13. Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
  14. Aurinia: 3Q Earnings Snapshot
  15. Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
  16. Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018
  17. Here's What Pushed Aurinia Pharmaceuticals Inc. Up 16.8% in September
  18. Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher
  19. The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594566
  2. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19534252
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 19533288
  4. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181212101
  5. SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] 181212061
  6. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181169640
  7. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181169602
  8. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181085767
  9. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181005014
  10. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181004970